2025-05-02 10:03:11
Latest Post
Godrej Agrovet Limited consolidated Q4FY25 net profit drops QoQ to Rs. 70.78 crores
L G Balakrishnan & Bros Ltd posts Rs. 84.03 crores consolidated profit in Q4FY25
Swastika Investmart Ltd Q4 FY2025 consolidated profit slumps to Rs. 27.17 lakhs
Vertex Securities Ltd consolidated Q4 FY25 loss at Rs. 53.99 lakhs
The Federal Bank Limited consolidated Q4FY25 PAT jumps to Rs. 1108.31 crores
Stock Report
Jubilant Life Sciences Ltd Q4 FY2020 consolidated net profit rises to Rs. 260.49 crore
Posted On : 2020-05-29 19:24:20( TIMEZONE : IST )
JUBILANT LIFE SCIENCES LIMITED has reported financial results for the period ended March 31, 2020.
Financial Results (Q4 FY19-20) - QoQ Comparison
The company has reported total income of Rs.2410.85 crores during the period ended March 31, 2020 as compared to Rs.2321.24 crores during the period ended December 31, 2019.
The company has posted net profit / (loss) of Rs.260.49 crores for the period ended March 31, 2020 as against net profit / (loss) of Rs.203.38 crores for the period ended December 31, 2019.
The company has reported EPS of Rs.16.35 for the period ended March 31, 2020 as compared to Rs.12.77 for the period ended December 31, 2019.
| Financials | Q4 FY19-20 | Q3 FY19-20 | % Change |
| Total Income | ₹ 2410.85 crs | ₹ 2321.24 crs |  3.86% |
| Net Profit | ₹ 260.49 crs | ₹ 203.38 crs | 28.08% |
| EPS | ₹ 16.35 | ₹ 12.77 | 28.03% |
Financial Results (Q4 FY19-20) - YoY Comparison
The company has reported total income of Rs.2410.85 crores during the period ended March 31, 2020 as compared to Rs.2379 crores during the period ended March 31, 2019.
The company has posted net profit / (loss) of Rs.260.49 crores for the period ended March 31, 2020 as against net profit / (loss) of Rs.(99.29) crores for the period ended March 31, 2019.
The company has reported EPS of Rs.16.35 for the period ended March 31, 2020 as compared to Rs.(6.38) for the period ended March 31, 2019.
| Financials | Q4 FY19-20 | Q4 FY18-19 | % Change |
| Total Income | ₹ 2410.85 crs | ₹ 2379 crs | 1.34% |
| Net Profit | ₹ 260.49 crs | ₹ (99.29) crs |  -362.35% |
| EPS | ₹ 16.35 | ₹ (6.38) | -356.27% |
Financial Results (12 months ended FY 19-20) - YoY Comparison
The company has reported total income of Rs.9201.84 crores during the 12 months period ended March 31, 2020 as compared to Rs.9146.56 crores during the 12 months period ended March 31, 2019.
The company has posted net profit / (loss) of Rs.898.24 crores for the 12 months period ended March 31, 2020 as against net profit / (loss) of Rs.574.46 crores for the 12 months period ended March 31, 2019.
The company has reported EPS of Rs.56.39 for the 12 months period ended March 31, 2020 as compared to Rs.36.86 for the 12 months period ended March 31, 2019.
| Financials | Year Ended FY19-20 | Year Ended FY18-19 | % Change |
| Total Income | ₹ 9201.84 crs | ₹ 9146.56 crs | 0.6% |
| Net Profit | ₹ 898.24 crs | ₹ 574.46 crs | 56.36% |
| EPS | ₹ 56.39 | ₹36.86 | 52.98% |
Commenting on the Company's performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences said: "We are glad to report record profits in FY20 with improvement in margins across all the business segments. The Q4FY20 performance was impressive with EBITDA growth of 58% YoY. Despite the Covid-19 led challenges, we continue to experience strong demand across most of our businesses. Our leadership position in all the segments we operate in ensures positive outlook for business performance and healthy cashflow generation to reduce leverage."
Pharmaceutical segment recorded revenue of Rs 5,714 Crore during FY20 as against Rs 5,349 Crore in FY19. The 7% YoY revenue growth during the year was driven by better performance in all three key business lines. EBITDA was at Rs 1,555 Crore, up 13% YoY with margin at 27.2%, as compared with 25.7% in FY19.
LSI segment's FY20 revenue was at Rs 3,179 Crore as against Rs 3,545 Crore last year. LSI's FY20 EBITDA was at Rs 431 Crore vs. Rs 445 Crore last year with margin at 13.6% vs. 12.6% last year.
The Drug Discovery Services business' FY20 revenue increased to Rs 262 Crore from Rs 217 Crore with 28.1% EBITDA margin in the current year as against 8.3% EBITDA margin in FY19. In view of the strong demand, we are making investments in this business to double capacities over the next 2-3 years.
In our Proprietary Drug Discovery business, we are working on more than six programs targeting small molecule therapies in the area of oncology and auto-immune disorders with two programs moving to the clinic next year.
During the year, the company reduced its Net Debt by Rs 514 Crore and is focused on further deleveraging by generating healthy levels of cashflows.
Company signed Licensing Agreement with Gilead Sciences to register, manufacture and sell Gilead's investigational drug, remdesivir, a potential therapy for Covid-19 in 127 countries including India, and is working towards launching the drug in July 2020.
The Company has taken several measures to tide over the COVID-19 induced challenges. We are confident of delivering sustained growth in the medium term on the back of our leadership position in various businesses and growth strategies.
Shares of JUBILANT LIFE SCIENCES LIMITED was last trading in BSE at Rs.442.25 as compared to the previous close of Rs. 434.75. The total number of shares traded during the day was 23170 in over 2082 trades.
The stock hit an intraday high of Rs. 453 and intraday low of 436. The net turnover during the day was Rs. 10301716.
